The UNK-MulTarget platform conjugates multiple targeting or drug molecules onto a single carrier scaffold, simultaneously recognizing multiple disease-related targets to build multifunctional molecular drugs — overcoming the limitations of single-target drugs such as single mechanism, drug resistance and limited efficacy, and adapting to innovative drug development for complex diseases such as oncology, autoimmune and metabolic diseases.
Advantages
Modular Assembly
Multiple independent conjugation sites on the carrier allow flexible combination of different targeting and effector molecules.
Synergistic Target Action
A single molecule acts on multiple disease targets simultaneously, achieving pathway synergy with improved efficacy and reduced resistance risk.
Uniform, Controllable Structure
Site-specific conjugation precisely controls the number and ratio of functional molecules, ensuring batch consistency.
Broad Disease Coverage
Supports early development of candidates for oncology, autoimmune and chronic metabolic diseases.
Principle
The carrier scaffold contains multiple independently drug-binding sites, enabling site-specific conjugation of targeting ligands, peptides or effector molecules at preset ratios. Through synergistic activation or inhibition of signaling pathways, it achieves multi-pathway intervention within a single molecular system — a “one drug, multiple targets” therapeutic model.
Applications
Based on the ZT-MulTarget platform, drug candidates for type 2 diabetes, obesity and MASH have been developed, providing entirely new approaches for complex and refractory diseases.
